RxDoctor Payments Data

Gloria Mays, APRN

Psychiatric/Mental Health · Ruston, LANPI 1194746362

Payments from drug & device makers

$991in general payments, 2019–2025

Across 19 payments — averaging $52.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$302
  • Neurocrine Biosciences, Inc.$125
  • Astellas Pharma US Inc$120
  • Otsuka America Pharmaceutical, Inc.$116
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$81
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$79
  • plus $169 from 6 others

What the payments were for

  • Food & beverage$991100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$991 in reported general payments places this provider in the 40th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$16,881
Medicare patients
82
Services billed
332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole51$38,074
NuplazidPimavanserin Tartrate12$29,585
NuedextaDextromethorphan Hbr/Quinidine14$5,504
Rivastigmine24$4,331
RivastigmineRivastigmine Tartrate36$2,379
Aripiprazole25$2,126
Memantine Hcl39$1,937
Mirtazapine57$1,379
Escitalopram Oxalate60$646
Olanzapine32$618
Quetiapine Fumarate47$481
Buspirone Hcl39$459
Gabapentin33$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$116$38,07451 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Ruston

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →